Cytogen, Inc. (KOSDAQ:217330)

Cytogen Statistics

Total Valuation

Cytogen has a market cap or net worth of KRW 93.09 billion. The enterprise value is 78.28 billion.

Market Cap	93.09B
Enterprise Value	78.28B

Important Dates

The next estimated earnings date is Friday, May 15, 2026.

Earnings Date	May 15, 2026
Ex-Dividend Date	n/a

Share Statistics

Cytogen has 23.07 million shares outstanding. The number of shares has increased by 2.17% in one year.

Current Share Class	23.07M
Shares Outstanding	23.07M
Shares Change (YoY)	+2.17%
Shares Change (QoQ)	+0.02%
Owned by Insiders (%)	27.14%
Owned by Institutions (%)	n/a
Float	8.44M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.57
PB Ratio	2.59
P/TBV Ratio	3.62
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-6.34
EV / Sales	3.00
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-8.77

Financial Position

The company has a current ratio of 2.93, with a Debt / Equity ratio of 0.45.

Current Ratio	2.93
Quick Ratio	2.59
Debt / Equity	0.45
Debt / EBITDA	n/a
Debt / FCF	-1.82
Interest Coverage	-3.50

Financial Efficiency

Return on equity (ROE) is -29.06% and return on invested capital (ROIC) is -8.79%.

Return on Equity (ROE)	-29.06%
Return on Assets (ROA)	-7.57%
Return on Invested Capital (ROIC)	-8.79%
Return on Capital Employed (ROCE)	-17.19%
Weighted Average Cost of Capital (WACC)	5.18%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.39
Inventory Turnover	6.69

Taxes

Income Tax	-611.72M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +29.34% in the last 52 weeks. The beta is -0.03, so Cytogen's price volatility has been lower than the market average.

Beta (5Y)	-0.03
52-Week Price Change	+29.34%
50-Day Moving Average	5,511.10
200-Day Moving Average	4,279.60
Relative Strength Index (RSI)	39.29
Average Volume (20 Days)	254,533

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cytogen had revenue of KRW 26.05 billion and -12.34 billion in losses. Loss per share was -535.00.

Revenue	26.05B
Gross Profit	5.61B
Operating Income	-8.16B
Pretax Income	-12.95B
Net Income	-12.34B
EBITDA	-4.99B
EBIT	-8.16B
Loss Per Share	-535.00

Balance Sheet

The company has 31.51 billion in cash and 16.28 billion in debt, with a net cash position of 15.23 billion or 660.31 per share.

Cash & Cash Equivalents	31.51B
Total Debt	16.28B
Net Cash	15.23B
Net Cash Per Share	660.31
Equity (Book Value)	35.99B
Book Value Per Share	1,541.19
Working Capital	28.48B

Cash Flow

In the last 12 months, operating cash flow was -6.95 billion and capital expenditures -1.97 billion, giving a free cash flow of -8.92 billion.

Operating Cash Flow	-6.95B
Capital Expenditures	-1.97B
Depreciation & Amortization	3.17B
Net Borrowing	-1.36B
Free Cash Flow	-8.92B
FCF Per Share	-386.85

Margins

Gross margin is 21.55%, with operating and profit margins of -31.33% and -47.37%.

Gross Margin	21.55%
Operating Margin	-31.33%
Pretax Margin	-49.71%
Profit Margin	-47.37%
EBITDA Margin	-19.15%
EBIT Margin	-31.33%
FCF Margin	n/a

Dividends & Yields

Cytogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.17%
Shareholder Yield	-2.17%
Earnings Yield	-13.26%
FCF Yield	-9.59%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 28, 2022. It was a forward split with a ratio of 3.

Last Split Date	Sep 28, 2022
Split Type	Forward
Split Ratio	3

Scores

Cytogen has an Altman Z-Score of 0.28 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.28
Piotroski F-Score	3